ReviewJACC. Asia2025
Epidemiology of Valvular Heart Disease in Asia Pacific Region.
Review in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Advancing the Evidence Base for Tricuspid TEER: Insights from the TEER-CHINA Trial.JACC. Asia · 2026Article
- Shifting From Anatomical to Functional Abnormalities.JACC. Asia · 2026Article
- Partnerships for Progress: Another Year of China Valve.JACC. Case reports · 2026Article
- Comparisons of the Burden and Quality of Care of Nonrheumatic Valvular Heart Disease in Asia and Globally.Journal of the American Heart Association · 2026Article
- Review
- What Will Define the Next Era of Transcatheter Aortic Valve Replacement: Cost, Volume, and Quality?JACC. Asia · 2026Article
- Beyond Cholesterol: Is High-Density Lipoprotein a New Prognostic Factor in Rheumatic Heart Disease?JACC. Asia · 2026Article
- Features and short-term outcomes of real-world transcatheter tricuspid valve repairAnnals of cardiothoracic surgery · 2026Article
- Development-adjusted inequities and temporal trends in rheumatic heart disease burden across ASEAN countries, 2000-2023.Frontiers in cardiovascular medicine · 2026Article
- Initial Real-World Experience of Tricuspid Transcatheter Edge-to-Edge Repair in Asia.JACC. Asia · 2026Article
- Echocardiographic Assessment of Patients Undergoing Mitral Valve Repair.Journal of cardiovascular development and disease · 2025Review
- Changing trends in burden of calcific aortic valve diseases and degenerative mitral valve diseases among people aged 60-89 years from 1990 to 2030.European journal of medical research · 2025Article
- Article
- The Persistent Burden of Rheumatic Heart Disease in Africa.JACC. Asia · 2025Article
- Reply: The Persistent Burden of Rheumatic Heart Disease in Africa.JACC. Asia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valvular heart disease poses a significant health burden in the Asia-Pacific region, with its epidemiology varying widely across countries caused by diverse socioeconomic and health care situations. Rheumatic heart disease remains prevalent, especially in low- to middle-income areas, while degenerative valvular diseases are emerging in developed regions caused by an aging population. Significant disparities in access to health care and intervention result in variable clinical outcomes. In the past decade, transcatheter interventions have revolutionized the management of patients with valvular heart disease globally. In the Asia-Pacific region, the uptake and development of transcatheter valvular interventions has been slow until recent years. Continued collaboration across the Asia-Pacific region is essential to mitigate the impact of the upcoming surge of valvular heart disease in this diverse and rapidly changing area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.